News

SOHO 2023: Final Overall Survival Trial Update on Combination Therapy in Myeloma

Study in France and Algeria: Unexpected Survival Similarities After ASCT in Myeloma

SOHO 2023: Personalized, Multidisciplinary Approach to Managing Myeloma in Frail Adults

Motixafortide Plus Filgrastim Approved by FDA for ASCT in Multiple Myeloma

Cryopreserved Autologous Peripheral Blood Hematopoietic Cells: Patterns in Use and Related Costs

Can Phenotypic Patterns in Multiple Myeloma Correlate With Clinical Outcomes?

Potential Immunogenic Cell Death–Related Predictor of Therapeutic Response in Myeloma

Researchers Focus on Affinity Tuning of CAR T Cells in Myeloma to Reduce Toxicity

Underrepresentation of Non-White Patients in Multiple Myeloma Clinical Trials

FDA Grants Accelerated Approval to Elranatamab-bcmm in Treatment of Relapsed or Refractory Myeloma

FDA Approves Talquetamab-tgvs for Treatment of Relapsed or Refractory Multiple Myeloma

Bortezomib-Induced Peripheral Neuropathy in Black Patients With Newly Diagnosed Myeloma

Use of Teclistamab in Patients With Myeloma Who Had Received Anti-BCMA Therapy

Real-World Analysis of Bridging Therapy Before CAR T-Cell Therapy for Resistant Myeloma

DREAMM-3 Trial: Belantamab Mafodotin Versus Pomalidomide Plus Dexamethasone in Relapsed Myeloma

Long-Terms Results With Isatuximab-Based Regimen for 1q21-Positive Patients With Myeloma

Final Analysis From CARTITUDE-1 Trial of Ciltacabtagene Autoleucel in Resistant Myeloma

Observations on Global Disparities in Toxicity From Myeloma Treatment

Does Bispecific Antibody Therapy for Relpased Multiple Myeloma Pose a Risk of Infection?

5-Year Follow-up of LEGEND-2 Trial of Immunotherapy for Resistant Myeloma

Can Clonal Diversity Complement MRD Assessment in Predicting Outcomes in Myeloma?

CARTITUDE-4 Shows Potential of Ciltacabtagene Autoleucel in Myeloma After First Relapse

Isatuximab With and Without Lenalidomide Under Study in High-Risk Smoldering Myeloma

Extended Follow-up From MagnetisMM-3 on Use of Elranatamab in Resistant Myeloma

Update From Phase II MonumenTAL-1 Study of Talquetamab in Resistant Myeloma

EHA 2023: Use of Idecabtagene Vicleucel in High-Risk Subgroups With Resistant Myeloma

ASCO 2023: New BCMA-Directed CAR T-Cell Therapy Under Study in Resistant Myeloma

EHA 2023: MRD as a Surveillance Tool in MASTER Trial of Quadruplet Therapy for Multiple Myeloma

ASCO 2023: Infection Profile and Immune Function With Talquetamab Monotherapy for Myeloma

EHA 2023: Research Explores T-Cell Exhaustion and CAR T-Cell Therapy for Myeloma

ASCO 2023: Maintenance Triplet Regimen for High-Risk Myeloma

EHA 2023: Therapeutic Implications of Distinct T-Cell Profile of Older Patients With Multiple Myeloma

ASCO 2023: New Data on Efficacy, Safety, Dosage of Bispecific Antibody Linvoseltamab

EHA 2023: Could the Oxidative Phosphorylation Pathway Be a Therapeutic Target in Multiple Myeloma?

ASCO 2023: CARTITUDE-4 Reports Benefit of Ciltacabtagene Autoleucel in Lenalidomide-Refractory Myeloma

ASCO 2023: Elotuzumab-Based Combination Regimen Under Study in First-Line Setting for Myeloma

ASCO 2023: Preliminary Results With Teclistamab Plus Talquetamab for Resistant Multiple Myeloma

ASCO 2023: TRIMM-2 Update Supports Steroid-Sparing Regimen for Resistant Myeloma

Bone Marrow Assessment of MRD as a Prognostic Tool in Multiple Myeloma

What We Know About the Association Among Diet, the Microbiome, and Multiple Myeloma

Treatment Algorithm for Patients With Myeloma and Light Chain Cast Nephropathy

Predicting Benefit of Elotuzumab in Myeloma: Novel Scoring System Focuses on Lymphocyte Counts and B2M

Next-Generation Sequencing and MRD Negativity in Multiple Myeloma

POMACE Phase II Trial in Myeloma: Combination of Bortezomib, Pomalidomide, and Dexamethasone

AACR 2023: Checkpoint Blockade and Multiple Myeloma–Specific Targeting May Enhance NK Cell Responses

AACR 2023: Cellular Membrane Lipid-Extracted Nanoliposomes in Multiple Myeloma

AACR 2023: Racial and Socioeconomic Influences on Access to Care in Multiple Myeloma

AACR 2023: First-in-Human Study Results on New Bispecific Antibody in Resistant Myeloma

AACR 2023: Does Race Play a Role in Progression of Myeloma Among Patients Being Treated for Diabetes?

AACR 2023: Strategies to Overcome Resistance to Chemotherapy in Patients With Myeloma

FDA Brief: Cell Therapy Approved to Reduce Infection Risk After Stem Cell Transplantation

AACR 2023: 3D Organoid Model as a Conduit for Studying Multiple Myeloma

Study Identifies Novel Diagnostic Tool for Patients With Multiple Myeloma

Exploring the Utility of Liquid Biopsy for Disease Evaluation of Multiple Myeloma

Final Analysis of PLEIADES and EQUULEUS: Treatment Insights on Daratumumab-Based Regimen

NCCN 2023: A Rare Case of Intratubular Cytoplasmic Amyloidosis in a Patient Without Myeloma

NCCN 2023: Update on Managing Resistant Myeloma

Are Carfilzomib-Treated Patients With Myeloma at Risk for Thrombotic Microangiopathy?

Novel Anti-CD38 Antibody Quadruplet Regimen for Newly Diagnosed Multiple Myeloma

Immunoglobulin J Chain: Potential Target of T-Cell Receptor–Based Therapy in Myeloma